MACSF Joins RDS Investor Pool With €1 Million Contribution

Medical device startup RDS has welcomed MACSF (Mutuelle d’Assurance du Corps de Santé Français) to its investor pool with a €1 million ($1.1 million) contribution, bringing the total funding raised since the company’s 2020 inception to €14 million ($15.3 million). The insurer also plans to contribute to RDS’ anticipated series A funding round.
 
This latest financing will help RDS with the commercial launch of MultiSense. The series A fundraising planned for later this year will facilitate MultiSense marketing in Europe, continued product development, the start of new clinical trials, and product registration with U.S. authorities, ready for its release in 2025.
 
“Welcoming MACSF on board as an investor is of course highly symbolic for RDS,” RDS CEO Elie Lobel said. “Beyond the improvement in patient care, our rollout of the MultiSense solution also has tangible positive impacts in terms of CSR and sustainability, in full alignment with MACSF’s investment policy.”
 
MultiSense is a Class IIa medical device providing healthcare professionals with a high precision, comprehensive, multi-parameter solution for continually monitoring patients’ health in the hospital or at home. The solution connects a wearable patch with a cloud-based platform and associated support services. The first version provides continuous measurement of six key parameters: heart rate, respiratory rate, oxygen saturation, skin temperature, patients’ level of activity and their posture. The product is protected by more than 20 patents. Sustainable development has been key from the start: the device can be cleaned, refurbished and reused, to minimize its carbon footprint. MultiSense is intended to make it easier to introduce short stay hospitalization protocols to reduce the average length of hospital stays, make hospital discharge safer and improve patients’ quality of life.
 
The global remote patient monitoring market was valued at roughly $53.6 billion (€49 billion) in 2022, and is expected to expand 26.7% annually through 2027. 

“MACSF is delighted to be joining forces with RDS in its approach, designed to improve quality of care, enhance patient safety, and optimize clinical time. This investment reflects our commitment to transforming medical practices to provide increasingly effective care to meet each individual’s needs,” MACSF Medical Director Dr. Thierry Houselstein stated.
 
A French insurer for healthcare professionals, MACSF has more than 100 years’ experience providing services to healthcare professionals. It employs 1,600 people and generates €3 billion ($3.3 billion) in revenue. MACSF provides cover for personal and occupational risks for more than 1 million members and customers.

RDS develops MultiSense, a next-generation remote patient monitoring (RPM) solution comprising a wearable patch monitor for collecting high-quality, real-time physiological data, in the hospital or at home, and a cloud-based platform for healthcare professionals to transform these data into actionable insights. MultiSense is protected by more than 20 patents and has been validated in six clinical trials. RDS has received numerous accolades, including the i-Lab prize in 2020, the Grand Prix de l’Académie des Technologies in 2022 and the i-Nov award in 2023. The company was founded in 2020 and is based in Strasbourg, France. It is incubated at SEMIA/Quest for Health and is part of the Future4Care accelerator program. It currently employs around 20 staff.